46/73
  • Pages
  • Editions
01 Cover
02 Welcome Letter / Sections
03 Article & Interview Directory
04 Section 1: Introduction
05 Introduction to US Life Sciences
06 Janssen Pharmaceuticals Interview
07 Investment Climate
08 MPM Capital Interview
09 Signet Healthcare Partners Interview
10 Xontogeny Interview
11 Insights from EisnerAmper
12 The Life Sciences Regulatory Climate
13 Buchanan Ingersoll & Rooney PC Interview
14 PhRMA Interview
15 PBOA Interview
16 Ernst & Young LLP Interview
17 LaVoieHealthScience Interview
18 Section 2: Introducing the Hubs
19 East Coast
20 BioNJ Interview
21 MassBio Interview
22 Pennsylvania Biotechnology Center Interview
23 West Coast
24 Biocom California Interview
25 QB3-Berkeley Interview
26 Section 3: Drug Discovery and Development
27 Therapeutic Fields On Fire
28 Insmed Interview
29 Mammoth Biosciences Interview
30 Innovations Enhancing the Patient Experience
31 Arcturus Therapeutics Interview
32 Karius Interview
33 Expert Insights: Targeted Therapeutics
34 First Wave BioPharma Interview
35 Aphios Corporation Interview
36 Section 4: Contract Manufacturing and Chemicals
37 A Shifting Landscape
38 Syngene International Interview
39 Cambrex Interview
40 Lubrizol Life Science Interview
41 Aenova Group Interview
42 Keeping Up With Demands
43 Cureline Interview
44 Interview: Murli Krishna Pharma
45 PsychoGenics Interview
46 Expert Insights: Innovative Technologies
47 AMPAC Fine Chemicals Interview
48 TCG Lifesciences Interview
49 CordenPharma Interview
50 Quotient Sciences Interview
51 A Post-Pandemic World
52 New Vision Pharmaceuticals Interview
53 Adare Pharma Solutions Interview
54 Ascendia Pharmaceuticals Interview
55 Chemicals Producers and Distributors
56 Brenntag North America Interview
57 BASF Pharma Solutions Interview
58 Section 5: Technology Services
59 Life Sciences Go Digital
60 RxS Interview
61 Insights from Markem-Imaje
62 AiCure Interview
63 WhizAI Interview
64 Section 6: Company Profiles
65 Brenntag Company Profile
66 Adare Pharma Solutions Company Profile
67 Quotient Sciences Company Profile
68 SK pharmteco Company Profile
69 AiCure Company Profile
70 Markem-Imaje Company Profile
71 TCG Lifesciences Company Profile
72 Murli Krishna Pharma Company Profile
73 Credits

Expert Insights: Innovative Technologies


Each service provider finds its own balance of diversifying, specializing and sophisticating its manufacturing capabilities to stand out in a sea of competition. From blow-fill-seal to biospecimens, below are companies that have invested into unique offerings.

“Our novel HSC Technology, an automated High-Throughput Self-Interaction Chromatography technology platform, cuts costs, time, and manpower needed to optimize formulations. We measure the second virial coefficient of the active pharmaceutical ingredient (API) in various excipients, and the data collected enters a neural network that scans for different combinations. The solubility process is reduced from one year down to just three months.”

Larry DeLucas, President, Soluble Biotech

“Our innovative liquid-liquid separators solve the most difficult separation problems with ease, eliminating the need to run batches at half capacity with slow settling times, allowing for continuous manufacturing. Our devices are directly scalable from lab to pilot to production, and customers like our products as they are easy to use and maintain with plug and play functionality at all scales.”

Andrea Adamo, Founder & CEO, Zaiput Flow Technologies

“Vetter manufactures orphan and ultra-orphan drugs in its active pipeline. Conversely, we see substances like insulin replacing GLP-1 analogue drugs for which we manufacture approximately 70 million syringes of the same kind. We have both small-scale and large-scale filling capabilities to serve customers in both the precision medicine and large-scale manufacturing spaces.”

Peter Soelkner, Managing Director, Vetter Pharma

“Blow-fill-seal affords a higher level of sterility due to the containment and limited human interaction in the manufacturing process. This process also enables us to mold a container into unique delivery systems to achieve specific therapeutic solutions as well as attain a superior level of filling accuracy.”

Paul Josephs, President & CEO, Woodstock Sterile Solutions

“Our R&D division has innovative techniques to allow water-soluble drugs to be layered using aqueous media. MKPPL has developed safe nanoparticles that encapsulate micronutrients and interact with the outermost layer of skin to enhance penetration and can be delivered through an oil platform. Our Liposomal nanoparticle approach can be utilized for administering vitamins through the dermal route and delivering antibiotics and anti–inflammatory agents through topical applications.”

Satya Vadlamani, Chairperson & Managing Director, Murli Krishna Pharma Pvt Ltd

Image courtesy of CDC on Unsplash

Next:

Interview: AMPAC Fine Chemicals